Welcome to our dedicated page for Science 37 Holdings news (Ticker: SNCE), a resource for investors and traders seeking the latest updates and insights on Science 37 Holdings stock.
Science 37 provides direct-to-patient clinical trial site and patient recruitment services for sponsors seeking to expand trial access beyond traditional research sites. Its updates commonly address the company’s Direct-to-Patient Site, Metasite™ and Patient Recruitment solutions, proprietary technology stack, in-house medical and operational support, nationwide recruitment, telemedicine-enabled oversight, research-grade nursing, and direct-to-patient logistics.
Science 37 news also covers FDA inspection outcomes, data quality and protocol-adherence processes, enrollment contributions in pivotal Phase 3 studies, logistics partnerships for investigational medicinal product delivery, corporate leadership changes, and operational infrastructure supporting clinical research from patients’ homes.
Science 37 Holdings, a leader in patient access to clinical trials, announced that it exceeded enrollment goals in a Phase 2 clinical trial for EP547, a treatment for Cholestatic Pruritus in Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis. Over a 20-month period, Science 37 enrolled 21% of participants, achieving an enrollment rate of 1 patient per month, significantly faster than the 0.1 patients per month at traditional sites. This was made possible through their proprietary Metasite™ and Patient Recruitment solutions, which broaden the pool of qualified participants beyond local trial site areas.
Science 37 Holdings, Inc. announced the successful outcome of its recent FDA inspection for the Science 37 Metasite™ virtual site model, focusing on critical areas like data integrity, subject safety, and Principal Investigator oversight. The inspection, conducted between February 26 and March 6, 2024, resulted in no significant issues identified, showcasing Science 37’s commitment to regulatory compliance and quality research. This milestone underscores Science 37’s ability to provide high-quality, compliant data and accelerate clinical research.
Science 37 Holdings, Inc. has been awarded the 'Clinical Efficiency Innovation Award' in the 8th annual MedTech Breakthrough Awards program for its transformative patient recruitment solution. The company's AI-powered patient screening capabilities and nationwide medical licensure have revolutionized the conventional recruitment methods, resulting in improved patient experience, increased randomization rates, and better site satisfaction.
Science 37 Holdings, Inc. announced its partnership with a leading biotech company for a Phase 3 asthma clinical trial, achieving 22x faster enrollment compared to traditional methods. Science 37 contributed 28% of study participants over 15 months, enrolling an average of 44 patients monthly, while brick-and-mortar sites enrolled only 2. The company's innovative approach significantly reduced the study's time-to-target enrollment, showcasing its effectiveness in accelerating clinical research.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.